ERBB2 and breast cancer: The log-rank test that included the three patients requiring special consideration of classification, showed a significant difference (P < .01) in the post-diagnosis median survival time among the luminal breast cancer group (n = 13, 70.0 days, 95% CI = 29–104 days), triple-negative breast cancer group (n = 7, 23.0 days, 95% CI = 12–46 days), and HER2-positive group (n = 9, 158 days, 95% CI = 6–187 days) (Fig. 3).